Prognostic value of BRAF mutation in glioblastoma

Authors

Ayesha Sohail, Aga Khan University
Qurat-Ul-Ain Virani, Aga Khan UniversityFollow
Hafiza Fatima Aziz, Aga Khan UniversityFollow
Muhammad Shahzad Shamim, Aga Khan UniversityFollow

Document Type

Article

Department

Neurosurgery

Abstract

With advances in molecular genetics, exploring targetable mutations for treating glioblastoma (GBM) patients, has become a centre of interest in modern day neuropathology. BRAF mutation has been extensively reported in several brain tumours. Recent studies report identification of BRAF mutation in GBM patients, especially isocitrate dehydrogenase wildtype glioblastomas (IDH-WT GBM), and its potential role in patient outcomes. Here we discuss the existing literature on the prognostic value of BRAF mutation in GBM.

Comments

Pagination are not provided by the author/publisher.

Publication (Name of Journal)

Journal of the Pakistan Medical Association

DOI

https://doi.org/10.47391/JPMA.24-05

Recommended Citation

Sohail, A., Virani, Q., Aziz, H. F., Shamim, M. (2024). Prognostic value of BRAF mutation in glioblastoma. Journal of the Pakistan Medical Association, 74(1).
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_surg_neurosurg/374